3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Multiple Myeloma
6
Neoplasms
5
Neoplasm Metastasis
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Vomiting
1
Stomatitis
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Alveolar Soft Part
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Paraproteinemias
1
Oncology Patients Receiving Chemotherapy
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Nausea
1
NSCLC
1
Mucositis
1
Mastocytosis, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Interventions
Cisplatin
6
Radiotherapy, Intensity-Modulated
4
Saline Solution
3
Injections
3
golotimod
2
avasopasem manganese
2
Water
2
Vitamin B 12
2
Standard of Care
2
RRx-001
2
Practice Guidelines as Topic
2
Gentamicins
2
Fibroblast Growth Factor 7
2
FGF20 protein, human
2
Drug Therapy
2
samital
1
regramostim
1
peppermint oil
1
meclocycline
1
hydrated silica gel-based toothpaste
1
holy basil leaf extract
1
cobiprostone
1
clazakizumab
1
calcium phosphate
1
brilacidin
1
anise oil
1
amlexanox
1
aluminum hydroxide, magnesium hydroxide, drug combination
1
Xylitol
1
Vincristine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Stomatitis
×
Diphenhydramine
×
Clear all
NCT02606994
2019-02-06
TPvsM
Oral Defense, LLC
Phase 2
Terminated
1 enrolled